Life Sciences

Former sales rep alleges J&J, Janssen pushed off-label promotion

Pharma Compliance Alert, March 11, 2009

Johnson & Johnson and its subsidiary Janssen Pharmaceutica directed sales representatives to promote Risperdal for off-label uses, according to a lawsuit by a former employee.

The FDA approved Risperdal to treat schizophrenia, but the companies encouraged physicians to prescribe it for off-label conditions such as bipolar disorder and depression, according to a Bloomberg.com article.

Read more about the lawsuit against J&J and Janssen.

Most Popular